BioCentury | Feb 7, 2011
Product Development

Keep It Simple

Genaissance Pharmaceuticals Inc. thought it would leverage its pharmacogenomics expertise in 2004 when it acquired Viibryd vilazodone , a compound that had failed five Phase II trials for depression. But the problem with Viibryd turned out...
BC Week In Review | Jan 24, 2011
Clinical News

Viibryd vilazodone regulatory update

FDA approved an NDA from Clinical Data for Viibryd vilazodone to treat major depressive disorder (MDD). Vilazodone is a mixed selective serotonin reuptake inhibitor (SSRI) and partial serotonin (5-HT1A) receptor agonist. Clinical Data obtained rights...
BC Week In Review | Dec 6, 2010
Company News

Clinical Data, Transgenomic deal

Transgenomic will acquire Clinical Data's genetic and pharmacogenomic testing and biomarker development business for approximately $15.4 million. The deal includes $6 million in cash, a three-year promissory note for $8.5 million that bears 10% interest...
BC Week In Review | May 31, 2010
Clinical News

Vilazodone regulatory update

FDA accepted an NDA from Clinical Data for vilazodone to treat major depressive disorder (MDD). The acceptance triggered a €12.5 million ($15.6 million) milestone payment to Merck KGaA (Xetra:MRK, Darmstadt, Germany), payable in 920,901 Clinical...
BioCentury | May 31, 2010
Finance

Regulatory milestones

Regulatory milestones Alkermes Inc. (NASDAQ:ALKS) was up $0.56 to $11.35 last week after FDA accepted for filing and granted Priority Review to an sNDA for Vivitrol naltrexone to treat opioid dependence. The injectable sustained-release formulation...
BC Extra | May 25, 2010
Company News

FDA accepts vilazodone NDA

FDA accepted an NDA from Clinical Data Inc. (NASDAQ:CLDA) for vilazodone to treat major depressive disorder (MDD). The acceptance triggered a EUR 12.5 million ($15.6 million) milestone payment to Merck KGaA (Xetra:MRK), payable in 920,901...
BC Week In Review | Mar 29, 2010
Clinical News

Vilazodone regulatory update

Clinical Data submitted an NDA to FDA for vilazodone to treat major depressive disorder (MDD). Vilazodone is a mixed selective serotonin reuptake inhibitor (SSRI) and partial serotonin (5-HT1A) receptor agonist. Clinical Data obtained rights to...
BC Week In Review | Jun 8, 2009
Clinical News

Vilazodone: Phase III data

Top-line data from a double-blind, U.S. Phase III trial (CLDA-07-DP-02) in 481 patients showed that oral vilazodone met the primary endpoint of a significant improvement in MADRS scores from baseline to week 8 compared with...
BC Week In Review | Dec 17, 2007
Company News

Clinical Data, Merck KGaA deal

MRK received a milestone payment of 135,146 shares from CLDA under a 2004 deal under which CLDA received rights to develop and commercialize the antidepressant Vilazodone (see BioCentury, Sept. 27, 2004). The shares are worth...
BC Week In Review | Nov 19, 2007
Clinical News

Vilazodone: Phase III start

In 1Q08, CLDA will begin a Phase III trial. The company obtained rights to Vilazodone through its 2005 acquisition of Genaissance Pharmaceuticals Inc. , which had acquired the compound from Merck KGaA (FSE:MRK, Darmstadt, Germany) in...
Items per page:
1 - 10 of 185
BioCentury | Feb 7, 2011
Product Development

Keep It Simple

Genaissance Pharmaceuticals Inc. thought it would leverage its pharmacogenomics expertise in 2004 when it acquired Viibryd vilazodone , a compound that had failed five Phase II trials for depression. But the problem with Viibryd turned out...
BC Week In Review | Jan 24, 2011
Clinical News

Viibryd vilazodone regulatory update

FDA approved an NDA from Clinical Data for Viibryd vilazodone to treat major depressive disorder (MDD). Vilazodone is a mixed selective serotonin reuptake inhibitor (SSRI) and partial serotonin (5-HT1A) receptor agonist. Clinical Data obtained rights...
BC Week In Review | Dec 6, 2010
Company News

Clinical Data, Transgenomic deal

Transgenomic will acquire Clinical Data's genetic and pharmacogenomic testing and biomarker development business for approximately $15.4 million. The deal includes $6 million in cash, a three-year promissory note for $8.5 million that bears 10% interest...
BC Week In Review | May 31, 2010
Clinical News

Vilazodone regulatory update

FDA accepted an NDA from Clinical Data for vilazodone to treat major depressive disorder (MDD). The acceptance triggered a €12.5 million ($15.6 million) milestone payment to Merck KGaA (Xetra:MRK, Darmstadt, Germany), payable in 920,901 Clinical...
BioCentury | May 31, 2010
Finance

Regulatory milestones

Regulatory milestones Alkermes Inc. (NASDAQ:ALKS) was up $0.56 to $11.35 last week after FDA accepted for filing and granted Priority Review to an sNDA for Vivitrol naltrexone to treat opioid dependence. The injectable sustained-release formulation...
BC Extra | May 25, 2010
Company News

FDA accepts vilazodone NDA

FDA accepted an NDA from Clinical Data Inc. (NASDAQ:CLDA) for vilazodone to treat major depressive disorder (MDD). The acceptance triggered a EUR 12.5 million ($15.6 million) milestone payment to Merck KGaA (Xetra:MRK), payable in 920,901...
BC Week In Review | Mar 29, 2010
Clinical News

Vilazodone regulatory update

Clinical Data submitted an NDA to FDA for vilazodone to treat major depressive disorder (MDD). Vilazodone is a mixed selective serotonin reuptake inhibitor (SSRI) and partial serotonin (5-HT1A) receptor agonist. Clinical Data obtained rights to...
BC Week In Review | Jun 8, 2009
Clinical News

Vilazodone: Phase III data

Top-line data from a double-blind, U.S. Phase III trial (CLDA-07-DP-02) in 481 patients showed that oral vilazodone met the primary endpoint of a significant improvement in MADRS scores from baseline to week 8 compared with...
BC Week In Review | Dec 17, 2007
Company News

Clinical Data, Merck KGaA deal

MRK received a milestone payment of 135,146 shares from CLDA under a 2004 deal under which CLDA received rights to develop and commercialize the antidepressant Vilazodone (see BioCentury, Sept. 27, 2004). The shares are worth...
BC Week In Review | Nov 19, 2007
Clinical News

Vilazodone: Phase III start

In 1Q08, CLDA will begin a Phase III trial. The company obtained rights to Vilazodone through its 2005 acquisition of Genaissance Pharmaceuticals Inc. , which had acquired the compound from Merck KGaA (FSE:MRK, Darmstadt, Germany) in...
Items per page:
1 - 10 of 185